4DMedical (ASX: 4DX) secures CE Mark for CT:VQ and raises A$83m to accelerate European commercial launch

4DMedical Limited (ASX: 4DX), the Melbourne-based respiratory imaging software company, has secured CE Mark certification for CT:VQ, its non-contrast, CT-based ventilation-perfusion imaging platform, enabling immediate commercial engagement with healthcare providers across the European Union. Simultaneous with the regulatory clearance, the company has completed an A$83 million institutional private placement at A$5.90 per share, raising a proforma cash position to A$289 million as at 31 December 2025. The dual announcement represents a material step-change in 4DMedical’s commercial footprint, adding the EU market, a population of more than 450 million with well-developed hospital imaging infrastructure, to the US and Canadian markets where CT:VQ already holds regulatory clearance. 4DX shares surged as high as A$7.55 in intraday trading on 27 March 2026, extending a 12-month run that has seen the stock appreciate more than 2,000% from A$0.315 a year ago.

What does CE Mark certification mean for 4DMedical’s CT:VQ commercial strategy in Europe and globally?

CE Mark certification is the regulatory gateway to commercial deployment across all 27 EU member states, a combined market that is widely regarded as one of the largest and most sophisticated in the world for advanced cardiothoracic imaging. Unlike the US pathway, which required separate FDA 510(k) clearance obtained in September 2025 alongside CMS reimbursement confirmation, the CE Mark process evaluates devices against EU medical device regulation standards and unlocks simultaneous access to the bloc’s member state markets. For 4DMedical, the significance is strategic as well as regulatory. Europe plays an outsized role in shaping global clinical practice in respiratory medicine, hosting a concentration of key opinion leaders, major academic research centres, and international respiratory congresses whose outputs influence adoption decisions in the US and elsewhere. Establishing CT:VQ within European clinical workflows creates reference data, publication opportunities, and clinician relationships that feed back into the broader global commercialisation narrative.

The technology itself addresses a structural gap in the European market. Ventilation-perfusion imaging is routinely used across EU healthcare systems for diagnosing pulmonary embolism and other cardiopulmonary conditions. Nuclear VQ scanning, the established method, relies on radioactive tracers and requires specialised infrastructure, both of which create access constraints in many European hospitals. CT:VQ bypasses this entirely by extracting ventilation and perfusion maps from standard non-contrast CT scans that hospitals already perform in large volumes. An estimated 400,000 nuclear VQ scans are conducted annually across the EU, and the addressable opportunity includes not only direct substitution of those scans but displacement into adjacent diagnostic pathways where nuclear options are unavailable or logistically prohibitive.

How does the A$83 million private placement position 4DMedical for European expansion and strategic acquisitions?

The placement was priced at A$5.90 per share, representing a 6.1% discount to the closing price on 26 March 2026 and a 12.3% premium to the five-day volume weighted average price. It is notable that the discount to last close is relatively tight by the standards of Australian biotech placements, which frequently clear at discounts of 10% to 15% or higher when momentum is absent. That investors committed at a narrow discount reflects both the quality of inbound institutional demand and the credibility of the CE Mark catalyst as a value inflection point. The placement will result in the issue of approximately 14.1 million new shares, increasing shares on issue by 2.45%, a dilution level that is modest relative to the capital raised.

Bell Potter Securities acted as lead manager and bookrunner. Proceeds are earmarked for the commercial launch of CT:VQ across Europe, clinical integration support for new European hospital customers, and general balance sheet strengthening to pursue strategic growth opportunities, including potential acquisitions. That final point is worth examining closely. The company enters this capital raise from a position of relative financial strength, with proforma cash of A$289 million reported as at December 2025. Adding A$83 million in fresh equity does not indicate operational necessity but rather signals that management intends to move at speed in Europe and is prepared to deploy capital on commercial infrastructure, market access partnerships, or bolt-on technology before the end of FY26.

Can 4DMedical replicate its US academic medical centre strategy in the European respiratory imaging market?

The US commercial playbook 4DMedical has executed since FDA clearance is disciplined and deliberate. The company targeted elite academic medical centres as launch partners, a strategy designed to generate credibility, publish clinical data, train future radiologists, and reduce friction in subsequent sales cycles across the broader hospital network. Within seven months of FDA clearance, CT:VQ had been deployed at six leading US academic institutions: Stanford Health Care, Cleveland Clinic, University of Miami Health System, UC San Diego Health, University of Chicago Medicine, and Mayo Clinic. The pace of conversion from evaluation to active deployment at this tier of institution is atypical for a new clinical imaging modality.

Europe presents a structurally analogous opportunity. The continent has a dense concentration of internationally recognised respiratory and cardiothoracic academic centres, many of which maintain active research collaboration with their US counterparts. The CE Mark opens the door to that network immediately, and the capital raised provides the resources to build a commercial organisation capable of executing clinical integration at multiple European sites simultaneously. The more substantive question is whether reimbursement pathways across EU member states will support commercial pricing structures comparable to those available in the US, where CMS classification under Category III CPT codes provides a formal revenue floor. EU member states operate separate national reimbursement frameworks, which vary significantly in timelines and reimbursement rates, and navigating that patchwork effectively will require dedicated regulatory and market access resources in key markets.

What are the competitive implications of CT:VQ entering the EU ventilation-perfusion imaging market now?

CT:VQ enters the European market with a meaningful first-mover position in non-contrast CT-based ventilation-perfusion imaging. There is no direct equivalent in commercial deployment within the EU at this time that combines ventilation and perfusion analysis from a standard non-contrast CT scan without requiring additional hardware or radioactive agents. The incumbent competing modality is nuclear VQ scanning, which is a decades-old technique with well-established clinical familiarity but significant operational constraints. For hospitals in rural or lower-resource European settings where nuclear medicine facilities are limited or absent, CT:VQ offers access to a diagnostic capability that would otherwise be unavailable, which is a different sales dynamic from displacement selling into established nuclear medicine departments.

Larger medical imaging platform companies, including Siemens Healthineers, Philips, and GE HealthCare, all have established EU presence and direct relationships with hospital procurement teams. 4DMedical’s existing commercial relationship with Philips in certain markets is relevant here, as a distribution arrangement with an established European healthcare infrastructure player would substantially accelerate hospital access. Whether 4DMedical pursues a direct sales model in Europe, a co-distribution arrangement, or a hybrid will be a critical strategic decision, and one the company has indicated it will clarify before the end of FY26.

How does the 4DX share price reaction reflect execution risk and the gap between regulatory milestones and commercial revenue?

The market response to the CE Mark and placement announcement was sharp. 4DX shares hit an intraday high of A$7.55 on 27 March 2026, a gain of more than 20% from the prior close of A$6.28, before retreating to around A$6.85 in morning trade. The placement price of A$5.90 represents a premium to where the stock was trading as recently as 18 March 2026, when shares were changing hands at A$3.87. The 12-month appreciation from A$0.315 to intraday highs above A$7 is a return of more than 2,000%, a trajectory that has few parallels among ASX-listed medical technology companies and reflects a market pricing in a long-duration growth runway rather than near-term earnings.

That gap between market enthusiasm and reported financials warrants attention. In the half-year to December 2025, 4DMedical reported revenue of A$2.85 million against a net loss of A$154.14 million. The consensus analyst revenue forecast projects growth to A$48.5 million by FY2028, implying compound annual revenue growth rates well in excess of 100%. At the same time, the average analyst 12-month price target available before today’s announcement was A$3.47, well below the pre-placement closing price of A$6.28, suggesting consensus had not fully incorporated the pace of regulatory approvals and institutional adoption. CE Mark certification in Europe changes the addressable market narrative in a meaningful way, but it does not close the execution gap between regulatory clearance and recurring commercial revenue generation at scale. That remains the central test for management over the next 12 to 24 months.

What execution and capital deployment risks does 4DMedical face as it enters the European respiratory imaging market?

Commercial execution in Europe requires building a market presence largely from scratch across a fragmented regulatory and reimbursement landscape. While CE Mark provides uniform product approval across the EU, commercial success depends on establishing reimbursement in individual countries, building clinical relationships with key European respiratory centres, hiring local commercial and clinical education teams, and managing the IT integration requirements of hospital PACS and DICOM systems that vary by country and institution. 4DMedical operates a software-as-a-service model that integrates into existing hospital infrastructure without requiring hardware changes, which reduces the physical installation burden, but clinical workflow integration and radiologist education remain time-intensive processes.

The company’s language around potential acquisitions as a use of the placement proceeds is strategically interesting but introduces additional execution complexity. Integrating an acquisition while simultaneously building out European commercial operations and maintaining US growth momentum would stretch management bandwidth and add balance sheet risk at a stage where the core commercial model is still being validated at scale. Investors with longer time horizons will note that 4DMedical’s proforma cash position, combined with the placement, provides a substantial funding runway, but the rate of cash consumption will accelerate meaningfully as European commercial infrastructure is built out.

Key takeaways: What 4DMedical’s CE Mark and A$83 million placement mean for investors, competitors, and the respiratory imaging industry

• CE Mark certification gives 4DMedical (ASX: 4DX) immediate access to the EU’s 450 million-person healthcare market, the most significant regulatory milestone for the company since FDA clearance in September 2025 and Canadian approval in December 2025.
• The A$83 million placement at A$5.90 per share cleared at a tight 6.1% discount to last close, reflecting strong institutional demand and market confidence in the CE Mark catalyst as a near-term value inflection point.
• Proforma cash of A$289 million as at December 2025, supplemented by fresh placement proceeds, gives 4DMedical a substantial runway to fund European commercial infrastructure and pursue acquisitions without near-term capital risk.
• An estimated 400,000 nuclear VQ scans performed annually across the EU represent the immediate addressable pool for CT:VQ displacement, with a larger longer-term opportunity in markets where nuclear imaging access is structurally constrained.
• The US academic medical centre playbook, six deployments at tier-one institutions in seven months, provides a proven template for European market entry, though country-by-country reimbursement complexity and the absence of a US-equivalent CMS framework will require dedicated market access investment.
• Nuclear VQ scanning incumbents and large imaging platform players including Siemens Healthineers, Philips, and GE HealthCare face a technically differentiated entrant that eliminates their key structural advantages of radiotracer dependency and specialist nuclear infrastructure.
• The 4DX share price has risen more than 2,000% over 12 months, reflecting a market pricing a long-duration growth thesis, but reported revenue of A$2.85 million in H1 FY2026 against a net loss of A$154.14 million underscores the size of the execution gap between regulatory clearance and commercial scale.
• Europe’s role in shaping global respiratory medicine through key opinion leaders and international congresses means clinical adoption at leading European centres has brand and publication value that translates into US and global commercial acceleration.
• The reference to potential acquisitions as a capital use signals strategic ambition beyond organic growth, though integrating acquisitions alongside a concurrent European commercial build-out carries execution and management bandwidth risk.
• Settlement of the placement is expected on 1 April 2026, with new shares commencing trading on 2 April 2026 under ASX Listing Rule 7.1, representing a 2.45% increase in shares on issue.